In its September issue, Pharmaceutical Commerce details the previous and expected contributions of biologic products to its forecast of cold-chain market growth predicting sales of cold-chain drugs and biologics will outpace overall industry growth through 2022. It is reported that “as of 2018, global...
Wednesday, September 12, 2018 | Read More
In a recent news release the FDA described research it has conducted regarding detection of protein carbonylation, an oxidative reaction that may occur in therapeutic protein drug products during manufacture, storage, use, and transport potentially causing structural alterations and threatening stability,...
Tuesday, September 11, 2018 | Read More
Sentry BioPharma Services is pleased to announce delegates from Sentry’s Business Development team will be in New York City attending the Drug, Chemical & Associated Technologies Association (DCAT) Week March 19th -22nd. The four-day conference brings together key sourcing, procurement and business...
Monday, March 19, 2018 | Read More
Sentry's Highly Protected Risk (HPR) facility is strategically located in Indianapolis, Indiana, the "Crossroads of America." This location enables Sentry to act as fast, expedient worldwide pharmaceutical distributors, providing a variety of built-in advantages for logistical efficiency.
Sentry's location is adjacent to Indianapolis International Airport, the eighth largest cargo airport in the U.S. The airport, just minutes away, serves 12 major airlines with more than 280 daily flights.
Four major interstates convene in Indianapolis (I-65, I-69, I-70 and I-74), providing one day driving access to 75% of all U.S. businesses.
Proximity to FedEx's 2nd largest hub enables Sentry to capitalize on late drop times, promoting effective west coast (U.S.) and global pharmaceutical distribution.